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Results
During follow-up, there were the following end points: ipsilateral stroke or TIA in 32; ipsilateral stroke alone in 10; any stroke in 18; and stroke death or CVD in 37; 29.1% of patients were using all 3 medical therapies and none of these patients experienced ipsilateral stroke during follow-up. The proportions of demographics, treatments, and RFs at each visit are shown in the Table and as follows.
1. Lipid-lowering therapy. The proportion of patients using any lipid-lowering or statin therapy changed significantly (both P<0.0001) between visits (Table) . Lipid-lowering therapy increased from baseline (65.8%) to 24 months (72.1%). Because statins were the predominant lipidlowering therapy, only effects of statins are presented in further analyses. 2. Antihypertensive therapy and hypertension. The proportion of patients using >3 antihypertensives increased from baseline (18.9%) to 24 months (23.6%) (Table) . Corresponding with this, there was a reduced proportion of patients who were hypertensive (BP >140/90 mm Hg) from baseline (14.7%) to 24 months (8.5%), and reduced mean systolic BP from baseline (147.5 mm Hg) to 24 months (141.5 mm Hg) over the same time period (Table) . 3. Antithrombotic therapy. The proportion of patients prescribed antithrombotics over the study duration altered significantly (P=0.003). However, overall, antithrombotics were prescribed at ≈95% of follow-ups. Anticoagulants or dual antiplatelet therapy were uncommon; therefore, only any antiplatelet (including dual) is presented in further analysis. Antiplatelets altered over follow-ups (P<0.0001); the major change was an increase at 6 months. There was no positive trend between use and study duration. 4. Smoking. Smoking status of patients varied between visits (P=0.017; Table) .
Relationship Between Treatments, Risk Factors, and Clinical End Points

Univariate Analysis
None of the baseline treatments predicted risk of ipsilateral stroke or TIA ( Figure 1 ). However, baseline mean BP weakly predicted any stroke or CVD death (P=0.03). In comparison to baseline measures, univariate associations between current treatments or RFs and subsequent risk are shown in Figure 2A and as follows.
1. Statins. Statins were associated with a lower risk of ipsilateral stroke or TIA (P=0.04) and of any stroke or CVD death (P<0.0001). 2. Antihypertensives and BP. Antihypertensives predicted a lower risk of ipsilateral stroke or TIA (P=0.01) and any stroke or CVD death (P<0.0001). BP was strongly associated with ipsilateral stroke or TIA and any stroke or CVD death (all P<0.0001). The association of antihypertensives with ipsilateral stroke or TIA was largely mediated via BP control ( Figure 2B ). 3. Antiplatelets. Antiplatelets predicted a lower risk of ipsilateral stroke or TIA and any stroke or CVD death (both P<0.0001).
Smoking.
Smoking was a predictor of risk of ipsilateral stroke or TIA (P=0.01) and any stroke or CVD death (P<0.0001).
Multivariate Analysis
Multivariate analyses were performed including antihypertensives, antiplatelets, and statins ( Figure 2C ). Antiplatelets (P<0.0001) were an independent predictor of a reduced risk of ipsilateral stroke or TIA. Statins, antihypertensives, age, and sex were not predictors of ipsilateral stroke or TIA. Antiplatelets (P<0.0001) and antihypertensives (P<0.0001) were independent predictors of a lower risk of any stroke or CVD death. Male sex (hazard ratios, 4.12; 95% confidence interval, 1.26-13.51; P=0.02) also was an independent predictor of any stroke or CVD death. Statins and age were not significant predictors of any stroke or CVD death. A multivariate analysis also was performed replacing antihypertensives with mean BP to determine the effectiveness of BP control for future risk ( Figure 2D ). Antiplatelets (P=0.001) and mean BP (P=0.002) were independent predictors of a reduced risk of ipsilateral stroke or TIA. Statins, age, and sex were not significant predictors of ipsilateral stroke or TIA. Antiplatelets (P<0.0001) were independent predictors of a lower risk of any stroke or CVD death. Mean BP (P=0.006) and male sex (hazard ratios, 4.72; 95% confidence interval, 1.45-15.38; P=0.01) also were independent predictors of any stroke or CVD death. Statins and age were not significant predictors of any stroke or CVD death.
Discussion
These results emphasize the importance of controlling conventional cardiovascular RFs in patients with asymptomatic carotid stenosis.
On univariate analysis hypertension, BP, smoking, statins, and antiplatelets all were associated with the end points. On multivariate analysis, antiplatelets and mean BP were associated with reduced ipsilateral TIA and stroke, whereas antiplatelets, mean BP, and antihypertensives were associated with any stroke or CVD death.
Patients were followed-up every 6 months and changes in treatment were recorded. Therefore, we associated current treatments and current RF with events in each subsequent 6-month period. This showed current treatments such as antiplatelets reduced the risk of stroke or TIA. The estimates for ipsilateral stroke or TIA favored statin and antihypertensives treatment, and for any stroke or CVD death the estimates favored statin treatment.
Antiplatelets are widely used in the secondary prevention of stroke, but evidence for their efficacy in primary prevention is less clear. 7, 8 One previous trial of aspirin in asymptomatic carotid stenosis 9 found no benefit, although this was performed some time ago (1988) (1989) (1990) (1991) (1992) (1993) (1994) when there was less effective treatment of vascular RF, and the annual rate of ischemic event was high, at ~11%. This study 9 included patients with ≥50% stenosis compared with the ≥70% stenosis cut-off used in our study. Our data suggest antiplatelets are important in patients with asymptomatic carotid stenosis. Because the majority of patients were only using aspirin, we did not have the power to examine efficacy between different or dual antiplatelets.
Limitations of this study include a lack of knowledge of the treatment duration before recruitment and lack of blood tests to assess efficacy of statin therapy, for example, achieved lowdensity lipoprotein cholesterol level; therefore, these could not be used to assess treatment efficacy. There was also an increase in statin and aspirin usage and a decrease in smoking from 1999 to 2009. However, the number of patients using statins in ACES is likely to be less than in current clinical practice, which may account for the nonsignificance of statins in the multivariate model. In addition, the study had a small sample size and follow-up for this study was 2 years; further data are required to show the effect of medical therapies Our data emphasize the importance of BP control in asymptomatic carotid stenosis. Mean BP was related to risk of stroke and TIA. On univariate analysis, antihypertensive use was related to a reduced ipsilateral stroke or TIA risk, but this association disappeared after controlling for mean BP level.
A considerable body of evidence has shown that statins reduce risk in stroke and atherosclerosis; the lack of effect we found with statin therapy may partly reflect the short time duration of follow-up. In the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial, 10 a reduction in risk only started appearing after 1 to 2 years of follow-up.
In summary, our data show that medical treatments can reduce risk in asymptomatic stenosis over relatively short time periods. This is consistent with recent clinical trials and epidemiological studies suggesting that intensive RF treatment significantly reduces stroke rate in asymptomatic carotid stenosis. Importantly, there were no ipsilateral strokes in any patient receiving all 3 medical therapies. Further trials are required to determine whether more intensive treatments will reduce the risk of stroke below that at which patients may benefit from interventions, such as carotid endarterectomy. Interestingly, in ACES, the risk of stroke was nearer to 1% (10/477) than 2%, suggesting stroke rates already may have decreased since the trials of endarterectomy in asymptomatic carotid stenosis were performed.
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None. Figure 2 . A, Associations with outcome accounting for changes every 6 months. Time-dependent age-and sex-adjusted univariate analysis for treatments and smoking for outcome of ipsilateral stroke or transient ischemic attack (TIA) and any stroke or cardiovascular death (CVD) death. B, Association of antihypertensives controlling for blood pressure. Time-dependent age-and sex-adjusted analysis for antihypertensive treatments adjusted for different blood pressure measurements for the different end points. C, Multivariate association of treatments with outcome accounting for changes every 6 months. Time-dependent age-and sex-adjusted multivariate analysis for treatments of outcome for ipsilateral stroke or TIA and any stroke or CVD death. D, Multivariate association of treatment and BP with outcome accounting for changes every 6 months. Time-dependent age-and sex-adjusted multivariate analysis for statins, antiplatelets, and blood pressure for outcome of ipsilateral stroke or TIA and any stroke or CVD death. BP indicates blood pressure; DBP, diastolic blood pressure; HR, indicates hazard ratio; mBP, mean blood pressure; SBP, systolic blood pressure; and PP, pulse pressure. 
Supplemental Material Supplemental Methods
ACES was designed to assess whether detection of embolic signals could predict stroke risk in patients with asymptomatic carotid stenosis. This was a post-hoc analysis of ACES 6 data.
Study inclusion criteria were: carotid stenosis (70-99% luminal occlusion, established by carotid duplex ultrasound), which had been asymptomatic for ≥2 years. Patients with previous symptoms in the contralateral carotid or vertebrobasilar territory were only eligible if symptoms were ≥2 years prior to recruitment. Patients with previous contra-lateral carotid endarterectomy (CEA) were eligible 1 year following surgery assuming they had remained asymptomatic in the territory of the operated artery since operation.
Exclusion criteria were: concurrent diseases likely to limit life expectancy to less than 3 years; if the patient, physician or surgeon was unwilling to manage asymptomatic carotid stenosis medically; absence of an acoustic window necessary for TCD, and the presence of non-biological prosthetic heart valves 7 .
Brain imaging with CT or MRI was performed at baseline. Subjects were followed at 6, 12, 18 months with final follow up at 24 months. If stroke or transient ischaemic attack (TIA) occurred during follow-up, a further brain CT or MRI was performed.
In addition to follow-up for new ischaemic events every 6 months, details of anti-platelets, anti-coagulants, anti- Anti-thrombotics prescribed were aspirin, Dipyridamole, Clopidogrel, Ticlopidine and other antiplatelets [trifusal, indobufene, picotamide] or any anticoagulation (heparin or warfarin) and combinations of anti-thrombotic therapies. This study was approved by the local ethics committees and all subjects gave written informed consent.
Atrial fibrillation(AF) was not an exclusion criteria and there were 35 patients with AF. Five had ipsilateral stroke/TIA and four of these were treated with CEA. One additional patient had vertebrobasilar stroke.
During follow-up there were 32 ipsilateral stroke/TIA, 10 ipsilateral stroke, 18 any stroke, 37 any stroke/CVD death 37. 34 patients had CEA: 16 after ipsilateral TIA, one after ipsilateral stroke, and 17 for asymptomatic stenosis. Follow up visits continued if a patient had a TIA, but stopped after a stroke or CEA.
Statistical methods
To analyse differences in treatments and BP between each follow-up period, Cochrans Q (dichotomous outcomes) or Friedmans ANOVA (continuous outcomes) test was performed in order to assess whether patients remained on the same treatments throughout the study period. Post-hoc Wilcoxon or McNemar tests for proportions were used (Bonferroni correction and p value ≤0.005 considered significant) where Cochrans Q was p<0.05 to observe where the difference in time points lay.
In standard Cox proportional hazards the risk of an event over time is related to variables which are assessed only at baseline, at the start of the follow-up period, however it relies on the assumption that these variables stay constant over time. During follow-up in studies with long duration (especially in observational studies), and with repeated follow-up these variables are likely to change and use of the baseline values will often not reflect subjects' current risk status. These changes can be incorporated into the prediction of stroke risk, by using timedependent Cox regression (which relaxes the assumption that variable stay constant over time) to calculate hazard ratios (HR) and their 95% confidence intervals (CI) for primary and secondary endpoints. Using the Time program (SPSS), time-dependent variables were defined and used to calculate risk at each time-point throughout the study. The current status of each time-dependent variable (e.g. statin treatment) at the start of each 6 month period was included and the time was defined until the start of the next 6 month period. Current treatment at the start of each six month period was therefore used to define risk over the subsequent 6 months until next clinical follow-up. The one HR given is the hazard ratio of outcome events over the subsequent 6 month period for not being currently on the treatment. P values <0.05 were considered statistically significant.
Univariate analysis of time-dependent covariates adjusted for age and sex was performed. The antihypertensive treatment time dependent covariate was analysed in combination with time dependent mean BP to examine whether changes in mean BP was an independent predictor of risk given anti-hypertensive treatment.
A multivariate analysis was then performed where all time-dependent covariates were analysed in backward Cox regression model adjusting for age and sex. This was performed by starting with all variables entered into the model. The parameters of all variables are then assessed. Those contributing are included into the final model, with age and sex forced "enter" into the model. The relationship between BP and stroke outcomes has been expressed using HRs associated with a 10mmHg increase in BP.
